Equity Overview
Price & Market Data
Price: $2.36
Daily Change: -$0.17 / 7.20%
Daily Range: $2.36 - $2.69
Market Cap: $167,940,432
Daily Volume: 686,328
Performance Metrics
1 Week: -15.71%
1 Month: -1.67%
3 Months: 95.04%
6 Months: 27.57%
1 Year: 16.83%
YTD: 7.76%
Company Details
Employees: 82
Sector: Health technology
Industry: Biotechnology
Country:
Details
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.